Halozyme Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell HALO and other ETFs, options, and stocks.

About HALO

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. 

CEO
Helen I. Torley
CEOHelen I. Torley
Employees
350
Employees350
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1998
Founded1998
Employees
350
Employees350

HALO Key Statistics

Market cap
8.26B
Market cap8.26B
Price-Earnings ratio
14.74
Price-Earnings ratio14.74
Dividend yield
Dividend yield
Average volume
2.97M
Average volume2.97M
High today
$71.80
High today$71.80
Low today
$69.54
Low today$69.54
Open price
$70.42
Open price$70.42
Volume
965.48K
Volume965.48K
52 Week high
$79.50
52 Week high$79.50
52 Week low
$42.01
52 Week low$42.01

Stock Snapshot

As of today, Halozyme Therapeutics(HALO) shares are valued at $70.26. The company's market cap stands at 8.26B, with a P/E ratio of 14.74.

On 2025-11-12, Halozyme Therapeutics(HALO) stock traded between a low of $69.54 and a high of $71.80. Shares are currently priced at $70.26, which is +1.0% above the low and -2.1% below the high.

Halozyme Therapeutics(HALO) shares are trading with a volume of 965.48K, against a daily average of 2.97M.

In the last year, Halozyme Therapeutics(HALO) shares hit a 52-week high of $79.50 and a 52-week low of $42.01.

In the last year, Halozyme Therapeutics(HALO) shares hit a 52-week high of $79.50 and a 52-week low of $42.01.

HALO News

Simply Wall St 1d
What Halozyme Therapeutics's Raised Guidance and Debt Moves Mean for Shareholders

In early November 2025, Halozyme Therapeutics reported strong third-quarter results with year-to-date revenue of US$944.84 million and net income of US$458.48 m...

What Halozyme Therapeutics's Raised Guidance and Debt Moves Mean for Shareholders
TipRanks 5d
Halozyme Announces Pricing of $1.3 Billion in Notes

Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions AI Analyst can help you make smarter investment...

Analyst ratings

55%

of 11 ratings
Buy
54.5%
Hold
45.5%
Sell
0%

People also own

Based on the portfolios of people who own HALO. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.